MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/jcma.0000000000001179

Медицинская библиотека · Journal of the Chinese Medical Association : JCMA · 2024

High-dose chemotherapy with autologous stem cell rescue in children and young adults with high-risk Ewing sarcoma.

Lee Chih-Ying, Hou Ming-Hsin, Hung Giun-Yi, Ho Cheng-Yin, Yu Ting-Yen, Wu Po-Kuei, Chen Chao-Ming, Yen Chueh-Chuan, Shiau Cheng-Ying, Chen Paul Chih-Hsueh, Wu Hung-Ta Hondar, Wu Ching-Lan, Yen Hsiu-Ju, Chen Wei-Ming

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

A combination treatment of surgery, chemotherapy, and radiotherapy can improve the survivals of pediatric patients with Ewing sarcoma (ES). However, prognosis remains poor for patients with metastatic disease at diagnosis or recurrence. Other high-risk (HR) features include large tumor burden, tumors of the axial skeleton, and poor histologic response. Several studies have documented high-dose chemotherapy with autologous stem cell rescue (HDC-ASCR) to be effective in such patients. In this retrospective study, we present the results of HDC-ASCR for high-risk ES (HRES) in children and young adults in a single institute.

METHODS

From March 2004 to March 2021, patients with ES, Ewing-like sarcoma, or round cell sarcoma received HDC-ASCR as part of treatment were included. The patients' characteristics, disease status, stem cell dose, engraftment status, post-transplant complications, and outcomes were analyzed.

RESULTS

Twenty patients receiving HDC-ASCR at complete response (n = 6), partial response (n = 13), and stable disease (n = 1) were enrolled. The male-to-female ratio was 11:9. Median age at diagnosis and transplant was 15.6 years old (range: 3.3-28.9) and 16.2 (range: 4.2-29.9), respectively. The conditioning regimens included ifosfamide-based in two and melphalan-based in 19. All patients achieved successful engraftment without transplant-related mortality. The 5-year progression-free and overall survival (OS) rate were 35% and 54.5%, respectively. The causes of death (n = 8) were all contributed to disease progression. Patients in the complete response group or with localized HRES exhibited a higher 5-year OS ( p = 0.047 and 0.05, respectively). Compared with the historical cohort without HDC-ASCR as part of primary treatment, the current cohort had a significantly better 5-year OS ( p = 0.018).

CONCLUSION

HDC-ASCR seems promising as an alternative treatment for HRES in improving OS in this retrospective study with a limited case number.

Для цитирования: Lee Chih-Ying, Hou Ming-Hsin, Hung Giun-Yi, Ho Cheng-Yin, Yu Ting-Yen, Wu Po-Kuei, Chen Chao-Ming, Yen Chueh-Chuan, Shiau Cheng-Ying, Chen Paul Chih-Hsueh, Wu Hung-Ta Hondar, Wu Ching-Lan, Yen Hsiu-Ju, Chen Wei-Ming. High-dose chemotherapy with autologous stem cell rescue in children and young adults with high-risk Ewing sarcoma.. Journal of the Chinese Medical Association : JCMA. 2024. DOI: 10.1097/jcma.0000000000001179.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.